Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by FUNDA MERIC-BERNSTAM and ARGUN AKCAKANAT.
FUNDA MERIC-BERNSTAM
Connection Strength
7.668
ARGUN AKCAKANAT
  1. Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. Clin Cancer Res. 2021 06 01; 27(11):3243-3252.
    View in: PubMed
    Score: 0.768
  2. MK-2206 window of opportunity study in breast cancer. Ann Transl Med. 2018 Nov; 6(Suppl 1):S57.
    View in: PubMed
    Score: 0.650
  3. Targeting translation initiation in breast cancer. Translation (Austin). 2014; 2(1):e28968.
    View in: PubMed
    Score: 0.476
  4. The rapamycin-regulated gene expression signature determines prognosis for breast cancer. Mol Cancer. 2009 Sep 24; 8:75.
    View in: PubMed
    Score: 0.346
  5. Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer. 2008 Jun; 112(11):2352-8.
    View in: PubMed
    Score: 0.316
  6. Rapamycin regulates the phosphorylation of rictor. Biochem Biophys Res Commun. 2007 Oct 19; 362(2):330-3.
    View in: PubMed
    Score: 0.299
  7. Anti-tumor activity and biomarker analysis for TROP2-antibody drug conjugate Datopotamab deruxtecan in patient-derived breast cancer xenograft models. Clin Cancer Res. 2024 Nov 25.
    View in: PubMed
    Score: 0.248
  8. Heterogeneous Profile of ROR1 Protein Expression across Tumor Types. Cancers (Basel). 2024 May 15; 16(10).
    View in: PubMed
    Score: 0.239
  9. Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer Discov. 2024 May 01; 14(5):828-845.
    View in: PubMed
    Score: 0.238
  10. Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer. Sci Rep. 2023 11 18; 13(1):20223.
    View in: PubMed
    Score: 0.231
  11. Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. NPJ Breast Cancer. 2023 Aug 11; 9(1):66.
    View in: PubMed
    Score: 0.226
  12. Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Sci Rep. 2022 01 24; 12(1):1248.
    View in: PubMed
    Score: 0.203
  13. Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancer Res. 2021 11 01; 81(21):5572-5581.
    View in: PubMed
    Score: 0.198
  14. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Res. 2021 03 04; 23(1):29.
    View in: PubMed
    Score: 0.191
  15. Targeting PI3K? alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss. Oncotarget. 2020 Mar 17; 11(11):969-981.
    View in: PubMed
    Score: 0.179
  16. TAK228 enhances antitumor activity of eribulin in triple negative breast cancer. Oncotarget. 2019 Aug 20; 10(49):5011-5019.
    View in: PubMed
    Score: 0.172
  17. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78.
    View in: PubMed
    Score: 0.170
  18. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6468-6477.
    View in: PubMed
    Score: 0.152
  19. Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer. Oncogenesis. 2017 Oct 09; 6(10):e385.
    View in: PubMed
    Score: 0.151
  20. Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Res. 2017 Aug 15; 19(1):93.
    View in: PubMed
    Score: 0.149
  21. Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2016; 11(3):e0151121.
    View in: PubMed
    Score: 0.135
  22. Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2015; 10(9):e0136851.
    View in: PubMed
    Score: 0.131
  23. Epithelial to mesenchymal transition is associated with rapamycin resistance. Oncotarget. 2015 Aug 14; 6(23):19500-13.
    View in: PubMed
    Score: 0.130
  24. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J Natl Cancer Inst. 2015 Mar; 107(3).
    View in: PubMed
    Score: 0.126
  25. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget. 2014 Sep 30; 5(18):8544-57.
    View in: PubMed
    Score: 0.122
  26. Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res. 2014 Jul 15; 20(14):3870-83.
    View in: PubMed
    Score: 0.120
  27. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?. Ann Oncol. 2014 Jun; 25(6):1122-7.
    View in: PubMed
    Score: 0.118
  28. Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surg Oncol Clin N Am. 2013 Oct; 22(4):641-64.
    View in: PubMed
    Score: 0.113
  29. High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Res Treat. 2013 Jan; 137(1):319-27.
    View in: PubMed
    Score: 0.108
  30. Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res. 2012 Oct 26; 14(5):R138.
    View in: PubMed
    Score: 0.107
  31. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res. 2012 Oct 15; 18(20):5816-28.
    View in: PubMed
    Score: 0.106
  32. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012 Mar 15; 18(6):1777-89.
    View in: PubMed
    Score: 0.103
  33. The effect of leucine restriction on Akt/mTOR signaling in breast cancer cell lines in vitro and in vivo. Nutr Cancer. 2011; 63(2):264-71.
    View in: PubMed
    Score: 0.094
  34. Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Mol Cancer Ther. 2010 Oct; 9(10):2770-84.
    View in: PubMed
    Score: 0.093
  35. Regulation and localization of ribosomal protein S6 kinase 1 isoforms. Growth Factors. 2009 Feb; 27(1):12-21.
    View in: PubMed
    Score: 0.083
  36. RNA-binding specificity of Y-box protein 1. RNA Biol. 2009 Jan-Mar; 6(1):59-64.
    View in: PubMed
    Score: 0.083
  37. eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther. 2008 Jul; 7(7):1782-8.
    View in: PubMed
    Score: 0.079
  38. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer. 2008 Mar; 15(1):257-66.
    View in: PubMed
    Score: 0.078
  39. RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient. Cancers (Basel). 2021 Sep 30; 13(19).
    View in: PubMed
    Score: 0.050
  40. Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway. Mol Ther. 2014 Jul; 22(7):1310-1319.
    View in: PubMed
    Score: 0.029
  41. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014 Apr; 2(4):361-70.
    View in: PubMed
    Score: 0.029
  42. Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin Cancer Res. 2013 Oct 01; 19(19):5474-84.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.